Sarepta COO has 24.8K shares withheld for taxes

Sarepta’s COO had shares withheld for taxes upon RSU vesting, and continues to hold a substantial direct equity position.

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. (SRPT) reported that Chief Operating Officer Ian Michael Estepan had 24,799 shares of common stock withheld on September 4, 2026 to satisfy tax withholding obligations related to the vesting of restricted stock units granted on September 3, 2025. The shares were valued at $22.22 per share for this withholding transaction, and Estepan now directly holds 177,184 shares of Sarepta common stock. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Tax Withholding: 24,799 shares

Tax Withholding 1 txn

Insider Estepan Ian Michael

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	24,799	$22.22	$551K

Holdings After Transaction: Common Stock — 177,184 shares (Direct)

Footnotes (1)

1. F1. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025.

Key Figures

Shares withheld for taxes: 24,799 shares Withholding valuation price: $22.22 per share Shares held after transaction: 177,184 shares +2 more

5 metrics

Shares withheld for taxes 24,799 shares Common stock withheld on September 4, 2026 to satisfy tax withholding obligations

Withholding valuation price $22.22 per share Valuation used for the 24,799 shares withheld for tax obligations

Shares held after transaction 177,184 shares Direct common stock holdings of COO Ian Michael Estepan following the transaction

Transaction date September 4, 2026 Date of the tax-withholding disposition of common stock

RSU grant date September 3, 2025 Date the restricted stock units that vested and triggered tax withholding were granted

Key Terms

restricted stock units, tax withholding obligations, Rule 10b5-1 trading plan

3 terms

restricted stock units financial

"vesting of restricted stock units granted on September 3, 2025"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"to satisfy tax withholding obligations related to vesting of restricted stock units"

Rule 10b5-1 trading plan regulatory

"No Rule 10b5-1 trading plan is reported for this transaction"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Sarepta Therapeutics (SRPT) disclose for its COO?

Sarepta disclosed that COO Ian Michael Estepan had 24,799 shares of common stock withheld on September 4, 2026 to cover tax withholding obligations arising from the vesting of restricted stock units granted on September 3, 2025.

Was the Sarepta (SRPT) COO’s Form 4 transaction a market sale?

No. The Form 4 reports a code F transaction, meaning 24,799 shares were withheld by Sarepta to pay tax withholding obligations tied to RSU vesting, rather than an open-market sale of shares by the COO.

At what price were the withheld Sarepta (SRPT) shares valued in the COO’s Form 4?

The withheld 24,799 shares were valued at $22.22 per share for the purpose of satisfying the COO’s tax withholding obligations related to the vesting restricted stock units.

How many Sarepta (SRPT) shares does the COO hold after this Form 4 transaction?

After the withholding of 24,799 shares for tax obligations, COO Ian Michael Estepan directly holds 177,184 shares of Sarepta Therapeutics common stock, as reported in the Form 4 filing.

Were the Sarepta (SRPT) COO’s transactions under a Rule 10b5-1 trading plan?

No. The filing indicates that the Rule 10b5-1 checkbox is not marked, so this withholding transaction is reported without being made pursuant to a Rule 10b5-1 trading plan.

What triggered the Sarepta (SRPT) COO share withholding for taxes?

The withholding of 24,799 shares was triggered by the vesting of restricted stock units that were originally granted on September 3, 2025, creating tax withholding obligations that the company satisfied by retaining shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 08:03 PM EDT Accepted by SEC EDGAR 09/08/2026 - 08:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Estepan Ian Michael

(Last) (First) (Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/04/2026		F(1)		24,799	D	$22.22	177,184	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Ian Michael Estepan	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)